Downgrades

Aurobindo Pharma's (ARBP) Q1FY26 EBITDA of Rs16.1bn (down 1% YoY) was 5% below our estimate led by lower US sales. Resultant our FY26 and FY27E EPS stands reduced by 5-10%. The company has maintained its 20-21% OPM guidance for FY26E despite gRevlimid sales loss. We expect margins and revenues to improve from H2FY26/FY27 with ramp up in PenG facility, Vizag pant commercialization and launches in US. We believe ARBP has multiple growth drivers in place with investments in vaccines, injectables, biosimilars...

Alembic Pharma’s (Alembic) Q1FY26 result was in line with our expectations. Revenue growth was mainly driven by US (13% YoY) and ex-US international business (21% YoY). India growth was tepid at 4.7% YoY due to challenges in specialty portfolio (up 1% YoY) and slowdown in acute market.

Finolex Industries' (FIL) Q1FY26 result was below our estimates on key parameters. The company experienced modest growth in pipes and fittings volumes, despite a weak overall demand scenario, however, operating performance was muted mainly due to weaker realization on account of volatility in PVC prices. The management guided that the demand has shown high single-digit growth as of early August 2025. The company expects this high single-digit trend to continue and is hopeful of crossing double-digit growth for FY26. Net sales declined by 8.5% YoY to Rs10.4bn, while EBITDA came in at...

JK Paper Ltd.'s (JK Paper) Q1FY26 result was broadly in-line with estimates on net sales and EBITDA front, while net profit was below our forecast. The Company's core business in Paper and Paper Board continued to face headwinds from cheap imports resulting in depressed sales realization and ongoing high domestic wood prices weighed on operating margin. Despite this, JK Paper improved its profits on a sequential basis. The management believes that packaging conversion business is amongst the fastest growing segments in the Indian Paper and Packaging industry driven by growth in end use industries....

We maintain our BUY recommendation on the stock with a TP of Rs 1,400/share.

We continue to maintain our HOLD rating on the stock.

Consolidated revenues fell 20% y-o-y to Rs. 371 crore as dispatches were delayed by geopolitical tensions across India, Iran and Israel.

Triveni Turbine (TRIV)’s 1QFY26 result was significantly lower than our expectations due to deferred dispatches and order execution. Geopolitical issues resulted in delayed customer decision-making regarding dispatches.

EPL reported an EBITDA of INR2.3b (+22% YoY) in 1QFY26, in line with our estimate. This was driven by EBITDA growth across all regions, with Europe/America/EAP/AMESA witnessing a growth of 52%/35%/8%/2% YoY.